MEDIPAL HOLDINGS and JCR Pharmaceuticals Sign Global Licensing and Japan Co-Development Agreement for JR-479, a Novel Therapy for GM2 Gangliosidosis

businesswire

MEDIPAL HOLDINGS and JCR Pharmaceuticals Sign Global Licensing and Japan Co-Development Agreement for JR-479, a Novel Therapy for GM2 Gangliosidosis – NEWSnet – News… as it used to be

More Press Releases

June 30, 2026

Autoliv Retires Repurchased Shares, Decreases Number of Issued Shares

June 30, 2026

JETOUR Hosted 2nd Boxy SUV Carnival to Advance Travel and Off-road Culture

June 30, 2026

Dominion Dynamics raises $139M CAD Series A to scale Arctic surveillance network and drone systems

June 30, 2026

MEDIPAL HOLDINGS and JCR Pharmaceuticals Sign Global Licensing and Japan Co-Development Agreement for JR-479, a Novel Therapy for GM2 Gangliosidosis

Autoliv Retires Repurchased Shares, Decreases Number of Issued Shares

JETOUR Hosted 2nd Boxy SUV Carnival to Advance Travel and Off-road Culture

Dominion Dynamics raises $139M CAD Series A to scale Arctic surveillance network and drone systems

Pan Finance Magazine Announces the Q2 Release and Award Winners of 2026